(NASDAQ: ARWR) Arrowhead Pharmaceuticals's forecast annual revenue growth rate of -20.41% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.98%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.98%.
Arrowhead Pharmaceuticals's revenue in 2025 is $545,209,000.On average, 8 Wall Street analysts forecast ARWR's revenue for 2025 to be $98,218,548,477, with the lowest ARWR revenue forecast at $75,292,357,162, and the highest ARWR revenue forecast at $108,519,321,823. On average, 8 Wall Street analysts forecast ARWR's revenue for 2026 to be $46,265,717,232, with the lowest ARWR revenue forecast at $14,044,814,240, and the highest ARWR revenue forecast at $75,513,317,858.
In 2027, ARWR is forecast to generate $49,593,247,213 in revenue, with the lowest revenue forecast at $19,154,530,335 and the highest revenue forecast at $74,933,296,031.